AbbVie reported that its dual-acting multiple myeloma bispecific antibody etentamig met the main goal of a Phase 3 trial, improving survival without progression for patients who had progressed on two or more prior lines. The company said independent trial monitors detected a difference at a pre-planned interim checkpoint. Etentamig is designed to bind both tumor cells and T cells to trigger immune attack, with AbbVie reporting low rates of serious immune responses compared with some rival bispecifics. The company framed this profile as potentially enabling broader use in community oncology centers by reducing post-treatment monitoring needs. In the trial, 421 patients were randomized to etentamig versus standard regimens, and 393 were evaluable at an average follow-up of about 11 months after trial entry. The program continues to face a class-wide evaluation challenge around managing cytokine release syndrome and ICANS risk. For the myeloma field, the result supports continued competition in T-cell engager strategies beyond CAR-T and highlights how safety and monitoring burden are becoming differentiators in late-stage readouts.